An antineoplastic medication, Lorbrexen is used in the treatment of cancer. It does this by inhibiting the growth of cancer cells, which in turn causes the body to destroy them.
Patients with ALK-positive non-small-cell lung cancer who have undergone prior treatment and are candidates for Lorbrexen, a third-generation anaplastic lymphoma kinase (ALK) anaplastic lymphoma kinase inhibitor, have shown to benefit from its anticancer properties (NSCLC).

When compared to crizotinib, it is unknown how effective Lorbrexen is as a first-line treatment for advanced ALK-positive non-small cell lung cancer (NSCLC).

None